



OPEN ACCESS

EDITED AND REVIEWED BY
Elke Bergmann-Leitner,
Walter Reed Army Institute of Research,
United States

*CORRESPONDENCE

Lorenzo Federico
✉ lorenzo.federico@medisin.uio.no
Ludvig Andre Munthe
✉ l.a.munthe@medisin.uio.no

RECEIVED 26 January 2024

ACCEPTED 05 February 2024

PUBLISHED 21 February 2024

CITATION

Federico L, Malone B, Tennøe S, Chaban V, Osen JR, Gainullin M, Smorodina E, Kared H, Akbar R, Greiff V, Stratford R, Clancy T and Munthe LA (2024) Corrigendum: Experimental validation of immunogenic SARS-CoV-2 T cell epitopes identified by artificial intelligence.
Front. Immunol. 15:1377041.
doi: 10.3389/fimmu.2024.1377041

COPYRIGHT

© 2024 Federico, Malone, Tennøe, Chaban, Osen, Gainullin, Smorodina, Kared, Akbar, Greiff, Stratford, Clancy and Munthe. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Corrigendum: Experimental validation of immunogenic SARS-CoV-2 T cell epitopes identified by artificial intelligence

Lorenzo Federico^{1,2*}, Brandon Malone³, Simen Tennøe³, Viktoriia Chaban^{1,2}, Julie Røkke Osen^{1,2}, Murat Gainullin^{1,2}, Eva Smorodina^{1,4}, Hassen Kared^{1,2}, Rahmad Akbar^{1,4}, Victor Greiff^{1,4}, Richard Stratford³, Trevor Clancy³ and Ludvig Andre Munthe^{1,2*}

¹Department of Immunology, Oslo University Hospital, Oslo, Norway, ²KG Jebsen Centre for B cell Malignancies, Institute of Clinical Medicine, University of Oslo, Oslo, Norway, ³NEC Oncology AS, Oslo, Norway, ⁴Institute of Clinical Medicine, Oslo University Hospital, Oslo, Norway

KEYWORDS

T cell, COVID-19, CD8+ lymphocytes, CD4+ lymphocytes, vaccine, SARS-CoV-2, artificial intelligence, antigen (Ag)

A Corrigendum on

Experimental validation of immunogenic SARS-CoV-2 T cell epitopes identified by artificial intelligence

by Federico L, Malone B, Tennøe S, Chaban V, Osen JR, Gainullin M, Smorodina E, Kared H, Akbar R, Greiff V, Stratford R, Clancy T and Munthe LA (2023) *Front. Immunol.* 14:1265044.
doi: 10.3389/fimmu.2023.1265044

Text correction

In the published article, there were two errors: The “Material and methods” section preceded the “Introduction” section, and there was an inaccuracy in the wording of a sentence in the “Reagents” sub-section of “Material and methods”.

The “Introduction” now precedes the “Material and methods”, and a correction has been made to a sentence in “Materials and methods”, sub-section “Reagents”.

This sentence previously stated:

“Peptides were synthesized by GenScript (Piscataway, NJ, USA) at a purity $\geq 85\%$, and used at a final concentration of 1.5mg/mL each.”

The corrected sentence appears below:

“Peptides were synthesized by GenScript (Piscataway, NJ, USA) at a purity $\geq 85\%$ and stored at a final concentration of 1.5mg/mL.”

The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated

organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.